445 related articles for article (PubMed ID: 25071314)
1. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?
Scalera A; Tarantino G
World J Gastroenterol; 2014 Jul; 20(28):9217-28. PubMed ID: 25071314
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1.
Shamardl HAMA; Ibrahim NA; Merzeban DH; Elamir AM; Golam RM; Elsayed AM
Daru; 2023 Jun; 31(1):13-27. PubMed ID: 36991247
[TBL] [Abstract][Full Text] [Related]
5. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.
Chun YS; Huang M; Rink L; Von Mehren M
World J Surg Oncol; 2014 Jul; 12():231. PubMed ID: 25052889
[TBL] [Abstract][Full Text] [Related]
6. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
7. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
9. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation.
Huynh H; Chow PK; Ooi LL; Soo KC
Cell Growth Differ; 2002 Mar; 13(3):115-22. PubMed ID: 11959812
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma.
Serradilla Martín M; Oliver Guillén JR; Palomares Cano A; Ramia Ángel JM
Rev Esp Enferm Dig; 2020 Feb; 112(2):133-138. PubMed ID: 32019315
[TBL] [Abstract][Full Text] [Related]
11. Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries.
Seyda Seydel G; Kucukoglu O; Altinbasv A; Demir OO; Yilmaz S; Akkiz H; Otan E; Sowa JP; Canbay A
Ann Hepatol; 2016; 15(5):662-72. PubMed ID: 27493104
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
13. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments?
Rosmorduc O
Ann Endocrinol (Paris); 2013 May; 74(2):115-20. PubMed ID: 23597944
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
16. Insulin-Like Growth Factor (IGF) System in Liver Diseases.
Adamek A; Kasprzak A
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29702590
[TBL] [Abstract][Full Text] [Related]
17. The IGF axis and hepatocarcinogenesis.
Scharf JG; Dombrowski F; Ramadori G
Mol Pathol; 2001 Jun; 54(3):138-44. PubMed ID: 11376124
[TBL] [Abstract][Full Text] [Related]
18. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
Michelotti A; de Scordilli M; Palmero L; Guardascione M; Masala M; Roncato R; Foltran L; Ongaro E; Puglisi F
Cells; 2021 Aug; 10(8):. PubMed ID: 34440803
[TBL] [Abstract][Full Text] [Related]
19. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.
Alexia C; Fallot G; Lasfer M; Schweizer-Groyer G; Groyer A
Biochem Pharmacol; 2004 Sep; 68(6):1003-15. PubMed ID: 15313394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
